Charles Russell Speechlys advises Apposite Capital on their investment into Mirada Medical
Charles Russell Speechlys has advised healthcare investor Apposite Capital on its £6m investment into medical imaging software business Mirada Medical Limited. Mirada is a leading developer of artificial intelligence (AI) based software which increases the speed and accuracy of cancer treatment planning applications, while delivering a more personalised level of care to patients. Apposite has invested alongside Mirada’s founding investor, Albion Capital, and other private investors.
Sam Gray, Partner at Apposite Capital, commented “We were delighted to work with Richard and team at Charles Russell Speechlys on this deal and appreciated their joined up approach and pragmatic and commercial outlook."
Richard Coleman, Private Equity Partner commented “Medical imaging continues to be enhanced by the possibilities of artificial intelligence and Mirada is at the forefront of those developments. We were delighted to be able to leverage our extensive medtech experience to assist Apposite on this investment."
The Charles Russell Speechlys team, led by Richard Coleman, comprised Rajiv Kakkad and Lydia Zakrzewski (Private Equity), Kirsti Laird (Employment), Caroline Young and Jaclyn Wilkins (Commercial and IP) and Helen Coward and Elliot Michaelson (Tax).
News & Insights
Charles Russell Speechlys advises Rockpool Investments on the buyout of Datum Alloys
Datum Alloys is the leading steel stencil foil manufacturer in Europe and the USA.
Model Clauses Update: Facebook’s appeal to stop the Irish High Court’s referral to ECJ on standard contractual clauses is dismissed
Are they now less attractive as a transfer mechanism?